Muthusamy Shanmugam Sells 9,520 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 9,520 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $65.40, for a total value of $622,608.00. Following the completion of the sale, the chief operating officer now owns 809,852 shares in the company, valued at $52,964,320.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ:ANIP opened at $64.58 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $36.99 and a 12-month high of $70.81. The business’s fifty day simple moving average is $64.77 and its 200-day simple moving average is $58.57. The company has a market capitalization of $1.36 billion, a PE ratio of 76.88 and a beta of 0.79. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ANIP shares. Capital One Financial started coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. Guggenheim raised their price objective on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. HC Wainwright raised their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, Truist Financial lifted their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $80.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its stake in ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock worth $1,471,000 after buying an additional 15,790 shares during the last quarter. BTC Capital Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter worth $580,000. Los Angeles Capital Management LLC grew its stake in ANI Pharmaceuticals by 27.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 24,974 shares of the specialty pharmaceutical company’s stock worth $1,726,000 after buying an additional 5,408 shares during the last quarter. Vanguard Group Inc. grew its stake in ANI Pharmaceuticals by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock valued at $71,074,000 after purchasing an additional 156,594 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $514,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.